Convergence of Healthcare with ICT accelerates

By Ping Shek

The healthcare market today is driven by the overriding need to deliver better patient care at lower cost, whilst being able to serve ever increasing numbers (from an aging population).  Technology and innovation are playing a key role in this.  The convergence of medical technology with information and communications technology (ICT) enhances the delivery of patient service whilst enabling more effective clinician workflow and healthcare provider administration.

The sale in June of Medical Insight, a Danish enterprise imaging software company, to Karos Health, a Canadian healthcare IT solutions provider, where PharmaVentures advised Medical Insight, is an example of this continuing consolidation trend.

The ‘electronic medical platform’ (‘EMP’), typically provided by ICT groups, is becoming the workflow and administration backbone for healthcare providers.  Medical equipment and devices, patient care venues (eg. operating room, radiology centre etc.), Accident and Emergency, ambulances, remote healthcare infrastructure are all integrated into the platform.  This architecture enables mobility, ‘seamless’ interconnection and much improved activity coordination.  The EMP plays a crucial role in the delivery of mobile health (mHealth), remote healthcare and home patient care, all of which play significant roles in helping achieve better patient care at lower cost.  Importantly, these electronic platforms can be provided using a Software-as-a-Service (SaaS) model which has distinct commercial advantages for ICT firms.

It is, therefore, not surprising that many ICT companies are starting to invest in technologies and/or partner with companies that enable them to better compete in this huge market.  For example, Google has struck up a strategic partnership with Alcon (Novartis) to develop its glucose eye monitoring contact lens; it also has an interest in DNAnexus, a bioinformatics company.  Cerner (a healthcare IT company) has teamed up with Siemens to jointly develop solutions in laboratory automation and cardiology information systems.  Dell acquired InsiteOne, a cloud-based medical data management systems.  Moreover, ICT groups are actively evaluating opportunities to gain access to the healthcare ICT market where the cloud SaaS segment is expected to grow at over 20% per year.

Going forward, we would expect ICT companies to increasingly partner with healthcare IT companies and medical device/equipment makers as part of process of developing the electronic medical platform and integrating technologies to ensure these platforms work effectively across the whole healthcare enterprise.  Further, we will see further consolidation in healthcare IT software companies as firms team up to provide more comprehensive IT solutions to healthcare providers that maximise the benefits of being connected to the EMP.  The sale in June of Medical Insight, a Danish enterprise imaging software company, to Karos Health, a Canadian healthcare IT solutions provider, where PharmaVentures advised Medical Insight, is an example of this continuing consolidation trend.

Pfizer/AZ: The bigger issue is not M&A but how in the future we find effective medicines

The debate and discussions in the media on the attempted bid by Pfizer for AstraZeneca (AZ) have largely revolved around the short term impact on jobs in the UK as well as the rights of shareholders and how corporations exploit tax loop holes.

The real question is how we as a society can actually find the drugs that are desperately needed for many incurable diseases? The Pfizer bid for AZ is only a symptom [no pun intended] of the continuous reconfiguring and restructuring of how pharmaceutical R&D can be performed so that we can efficiently find these cures.

How drugs are selected and finally make it to market is determined, quite correctly, through the scrutiny of the regulatory authorities such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). There is an inherent risk in taking a drug through clinical trials and less that 10% of drugs entering human clinical trials will make it to the patient. So how can companies reduce this risk and increase the chances of success?

Pharmaceutical companies have been grappling with the ‘how’ for the past two decades. Further more in recent years the landscape has been changing, for example, the regulatory hurdles, quite correctly, have been raised so the chances of finding the ‘right’ drug are lower and so more difficult. Both the pricing and reimbursement (P&R) of drugs place additional hurdles and additional risk on whether drug actually gets to the patient. In the UK P&R is regulated through the UK’s Department of Health via the Pharmaceutical Price Regulation Scheme (PPRS) and the National Institutes of Care Excellence (NICE) respectively. This changed landscape has meant that pharmaceutical companies have had to rethink how they do research. The concept of large companies doing all their own drug research has been on the wane for years. Great ideas cannot emerge in one place they happen everywhere and there is evidence that smaller R&D groups are more productive than large ones. As such pharmaceutical companies have become more dependent on external R&D provided by universities, charities and venture capital backed biotechnology (biotech) companies. Moreover, pharma companies have been refocusing their efforts to a smaller group of therapeutic areas with the greatest unmet clinical need. For the past five years all major pharmaceutical companies have been reducing their internal R&D efforts and this, by the way, independent of the world economy.

Furthermore pharmaceutical companies have been moving their R&D activities to locations with the highest research skills, these include Cambridge, Mass, and Cambridge, England. This has meant moving away from ‘remote’ R&D sites which originated as manufacturing sites, such as AstraZeneca closing its Cheshire, Alderley Park site and moving to Cambridge and Pfizer moving away from Sandwich in Kent. Most of the large pharmaceutical companies have done similar moves.

This changed landscape means that pharmaceutical companies have had to raise the scrutiny of their existing drug candidates and abandon more of them. To replace them they need to either find more candidates from biotechs or acquire them through acquisitions like Pfizer’s bid for AZ or through deals such as Novartis acquiring GSK’s oncology franchise.

In the end a key driver is a focus on building the strongest product pipeline. Simply put companies can strengthen their pipeline through acquisition by keeping the best of the combined businesses and spinning out or axing the weaker candidates.  Regardless of whether Pfizer acquires AZ or not, the change in ‘how’ R&D is done will lead to further rationalisation of R&D and a greater role for biotech to be the key innovators and, as such, we should see a further rise in M&A as well as licensing and partnerships. 

Pfizer+AZ: Will Mega-Merger Mania Return?

Today the talking point, of course, is the bid by Pfizer for AstraZeneca (AZ)  and whether this is good or bad for pharmaceutical companies, biotechs, R&D, employees, jobs and patients. One thing is for sure and that is the concept that pharma mega-mergers are a thing of the past has just been blown to pieces! So why should we see the return of the pharma mega-merger, what are the drivers and its implications?

My view is that this bid is just an elaborate extension of what pharma has been doing for the past five years, buying biotech companies and their assets to boost their pipelines. AstraZeneca’s patent cliff meant that it’s real value remains in it’s R&D. As I said in Saturday’s FT (3rd May 2014) “The environment has changed. The reasons ‘megamergers’ happened before are different from today. Pfizer’s bid for Warner Lambert was for a product already on the market. This time it is about access to the R&D pipeline.” 

The public financial markets tend to put lots of emphasis on earnings to the valuation of companies and little emphasis on their R&D pipeline. Pfizer’s move enables a strategic buyer, who wants to boost their R&D pipeline, an opportunity to acquire an undervalued publicly quoted company with a strong but undervalued R&D pipeline. AZ recognises this and has used the more conjectural based expected net present value (eNPV) valuation method to argue for a higher price, which at the time of writing appears to be working.

Yes, Pfizer will use its ‘off-shore’ cash pile to do the acquisition but that is just an extremely cheap source of capital to allow it to pay more for AZ. It is an extremely tax efficient use of that cash pile and it enables Pfizer to take the some additional risk on the acquisition. Although 68% of the last rejected offer was in the form of stock Pfizer is under pressure to move the cash component up so that AZ shareholders get more cash for their shares.

So what is the impact on other pharma companies and their employees? Well, as I write every major pharma company board has met or is about to meet to discuss their place in this new landscape and their own fate. If AZ is acquired the shape of the competitor landscape will have changed dramatically and they will feel that they have to respond. They are not going to sit there and ignore it, are they? So the next step will be a wave of mega-mergers probably reducing the number of large players up to one half their number in the next five years. A key driver will be a focus on building the strongest pipeline. Simply put, you can strengthen your pipeline through acquisition by keeping the best of the combined businesses and spinning out or axing the weaker candidates. Underlying this driver is the current definition of a weak drug candidate as this has changed dramatically as pharma has realised that clinical efficacy is simply not good enough. Pricing and reimbursement (P&R) and emergence of tougher bodies to regulate P&R have emerged to expose weak drug candidates in their existing pipelines.

Inevitably some of these mergers will be successful some not so successful. Rationalisation will mean that another wave of job losses will occur.

What will the impact be on the sector itself? I believe this will lead to further rationalisation of manufacturing and R&D and a greater role of out-sourcing to contractors. A trend that has been happening for some time and where we have had considerable experience. Indeed, one of our major pharma clients, where we acted as advisors, has just two days ago successfully sold one of its US manufacturing facilities to a US-based CMO. Pharma will continue to rely on biotech to be the key innovators and we should see a further rise in licensing and partnerships.

What about jobs? Some jobs will be lost forever. Individuals affected will either leave the sector completely, become entrepreneurs in new ventures or find jobs in the successful expanding parts of the sector, including in the stronger merged pharma companies.

Last, and by no means least, what about patients? In the end patients need access to drug therapies that are both effective and affordable. Both of these two elements are out of their control, they are dependent on a strong buoyant biotech sector to discover them, efficient well-capitalised pharmaceutical companies to take the risk to develop and commercialise them, and a private and public payer sector willing to pay for them. 

Pharma is attracted to early-stage antibody deals in Oncology


Today, the top ten best-selling antibody therapeutics for cancer have accumulated revenues approaching $200 Billion.  

Antibody therapies are successful in increasing patient survival; however, statistics show that there is still room to significantly improve clinical benefits. 


Until more companion biomarkers become available, early utility of high cost antibody therapeutics is unlikely to become mainstream. While antibody therapeutics for cancer clearly offer clinical benefits over other drugs, the cost of development and manufacture is high.  In many cases, these therapies only extend life by a relatively small amount and thus their high costs are sometimes hard for payers to justify. 

 Deal trends over the last five years reveal an increase in antibody deals in oncology from 2009 to 2011 and then a plateau until 2013. Discovery and pre-clinical stage deals prevail in oncology antibody therapeutics, as opposed to other therapeutic areas, where the majority of deals are being made in later Proof of Concept (POC) and Proof of Principle (POP) stages. Late-stage deals generally command larger upfront payments by the licensee, as much of the risk has been mitigated and paid for by the licensor. Higher up-fronts can make a deal unattractive if insufficient scope remains for the licensee to generate adequate return on their investment despite the higher probability of the therapy making it to market.  

On the contrary, in early-stage deals, only a low upfront payment is usually at risk but is coupled with a high overall deal value incorporating significant milestone payments that may never become due if the drug fails in later stages of development. It is w

orth noting that the number of late-stage deals has been declining, while the average deal value for discovery stage assets is significantly higher than might be expected. Gaining rights to early-stage assets gives the licensee more flexibility to shape its development. Furthermore, early-stage assets often comprise of “platforms” which could deliver multiple new drugs. These are often captured through option deal mechanisms. Increased competition for early stage assets appears to be driving total deal values higher in this sector.

​Deeper analysis of discovery stage deal values show rises up to 2011, but then a decline in 2012 and a major drop in 2013. This might reflect satisfaction of short-term pipeline needs of major Pharma companies and an increase in acquisition of assets or single asset companies rather than licensing.

 A clear picture emerges of where Big Pharma is currently spending their deal money. Stand-out areas are platform technologies such as Antibody Drug Conjugates (ADCs) and the new approach tackling checkpoint inhibitors. As such, the majority of Big Pharma companies are following antibody-based oncology therapies. It will be exciting to see how these new technology combinations emerge as new classes of cancer treatments and if they will address the cost / benefit conundrum that will allow earlier patient treatment and improved patient outcomes.

To download the full whitepaper click here.

Can 2014 be better than 2013?

I predict that 2014 will be a year where the pharmaceutical industry will be stronger, however, both old and new investment challenges will continue to behold biotech companies.

Through the painful process of restructuring, together with a strong therapeutic focus on their late stage clinical pipeline, a number of pharmaceutical companies will emerge in 2014 in a much stronger position than they were just a few years ago. Pharma has learnt to be lean and focussed. The challenges have not gone away and repeated drug failure in Phase III for some still needs to be dealt with.  One of the questions for pharmaceutical companies in 2014 is how they should build their emerging market strategy. Establishing a robust presence in the BRICs is proving more of challenge than anticipated. Although there have been some acquisition opportunities most pharma companies currently rely heavily on organic growth within these territories where business and cultural practices can be quite different. Nevertheless I predict a leaner and stronger pharma industry in 2014.

In 2013 we had the heady boom in biotech IPO’s in the US together with a strong rise in biotech stocks. Although this was very welcome and long over due it leaves the biotech sector with big challenges in 2014. The key question of course is the sustainability of the IPO market. Will we run out of good IPO candidates leading to the trap of poorer quality companies attempting to go public? I fear ‘probably’! And how sustainable is the market price for those companies that floated in 2013? This is not trivial! Their performance in 2014 can hugely influence investment in the biotech sector world-wide. For biotech companies generally 2013 was an ‘OK’ year. Good companies got funding, albeit not at ideal levels, but there was a general feeling of mild optimism. The lack of VC funding remains a big challenge particularly at the earlier stages of drug development. However, more imaginative schemes, some governemnt backed are starting to emerge.  This together with the rise of corporate VC funds will improve funding in 2014. Nevertheless, I believe there is a huge opportunity for new funds which can exploit the very much changed biotech industry. The old VC funding model is dead and stronger more intellient models are starting to emerge. So with a maturer and more experienced biotech sector I remain optimistic for 2014.

With all its knocks over the past decade I believe we have built a stronger industry capable of delivering its promise to patients. 2014 will be a year that will bring that promise closer.